United States Patent 5,981,589: Scope, Claim Strength, and U.S. Patent Landscape for Copolymer-1 (5–9 kDa)

What does claim 1 actually cover?

U.S. Patent 5,981,589 claims Copolymer-1 (also referred to in the art as glatiramer acetate / copolymer-1 material variants, depending on exact composition and salts) under a product-by-process structure tied to a narrow molecular-weight band and a specific deprotection/recovery route.

Claim 1 (as provided by you) is limited to:

Product identity: “Copolymer-1”
Product specification: molecular weight about 5 to 9 kilodaltons (kDa)
Manufacturing sequence (three functional steps):
1. Reacting “protected copolymer-1” with hydrobromic acid to form a “trifluoroacetyl copolymer-1”
2. Treating the trifluoroacetyl copolymer-1 with aqueous piperidine solution to form “copolymer-1”
3. Purifying the resulting copolymer-1
Outcome constraint: the final copolymer-1 has MW about 5 to 9 kDa

Net scope effect: even if “Copolymer-1” is broadly defined elsewhere in the specification, claim 1 narrows the enforceable subject matter to Copolymer-1 variants that end up in the ~5–9 kDa molecular-weight window and that are produced by (or characterized by) that specific protected-to-trifluoroacetyl-to-deprotected (piperidine) pathway.

How is the claim constructed legally (product-by-process)?

Claim 1 reads as product-by-process: it defines the product (Copolymer-1, MW 5–9 kDa) but ties that product to a specific process.

Scope implications for enforcement

For infringement analysis, the key question is whether accused products are:
- Copolymer-1 with MW ~5–9 kDa, and
- made by the claimed process steps or a process that achieves the same protected-to-trifluoroacetyl-to-piperidine recovery mechanism with the same end MW band.
For validity, the narrow MW band plus the specific chemical steps can reduce “general prior art” overlap, but can also create vulnerability if prior art discloses:
- the same MW range, and
- the same deprotection chemistry (HBr, trifluoroacetyl intermediate, aqueous piperidine).

Where is the claim narrowest?

The claim narrows at four choke points:

1) Molecular weight window

The product is limited to about 5 to 9 kDa. That is tighter than “copolymer-1” generically.

Enforceability lever: any commercial Copolymer-1 batches outside the window (even if close) can fall outside claim scope if “about” is construed narrowly in practice.

2) The identity of the intermediate sequence

The claim defines an intermediate:

trifluoroacetyl copolymer-1 and requires creation of that intermediate by:
reacting protected copolymer-1 with hydrobromic acid.

This is a chemically specific pathway. If prior art uses different deprotection chemistry (acid type, base type, or different protecting group removal route), it can weaken anticipation arguments.

3) Use of aqueous piperidine

The step:

treating trifluoroacetyl copolymer-1 with aqueous piperidine is the final conversion to Copolymer-1.

This is a strong scope delimiter because piperidine deprotection routes are not universally the same across peptide or copolymer deprotection workflows; it is a specific choice of base and medium.

4) Purification as a required final step

The claim requires purifying copolymer-1 after piperidine treatment.

While purification is often inherent to manufacturing, including it can matter if an accused process skips a purification stage or does not produce a product meeting the stated MW and characterization.

What does the claim NOT cover?

Based on the text of claim 1 you provided, the claim does not appear to cover:

Copolymer-1 produced with different deprotection chemistries (different acid than hydrobromic acid, different base than piperidine, or skipping the trifluoroacetyl intermediate).
Copolymer-1 with MW outside 5–9 kDa, even if made by the same overall concept.
Copolymer-1 defined only by general composition without the specified MW constraint.
Variants where “protected copolymer-1” is produced differently such that the claimed transformation sequence does not occur as written.

What is the patent landscape in the U.S. likely to look like around this claim?

Even without expanding beyond your claim text, the landscape around Copolymer-1 in the U.S. typically clusters into three functional buckets:

Composition/material definitions and manufacturing routes that define specific molecular-weight distributions or processing conditions.
Protecting group chemistry and deprotection steps used to manufacture copolymer materials with defined end characteristics.
Formulation patents (salt form, dosage forms, delivery systems), which are outside your claim’s process-limited product frame unless they tie back to the specific MW and process sequence.

Practical consequence for freedom-to-operate (FTO)

For a competitor manufacturing Copolymer-1 targeting a ~5–9 kDa band, the risk posture is driven by:

whether their process uses hydrobromic acid to produce a trifluoroacetyl intermediate, and
whether they then use aqueous piperidine to produce Copolymer-1 and then purify.

If those chemical steps are present, the MW target creates a direct claim hook.

If those steps are absent, the MW target alone is less likely to trigger claim 1, because the claim includes a process limitation in its product-by-process structure.

Claim charts: the minimal infringement mapping elements

Below is the claim-to-element mapping for claim 1 as supplied.

Claim 1 element-by-element breakdown

Claim element	What must be present for coverage
Copolymer-1	Accused product is Copolymer-1 (as understood by the patent’s definitions)
MW about 5 to 9 kDa	Accused product falls within the stated MW window (“about” constrains scope)
Protected copolymer-1 + HBr → trifluoroacetyl copolymer-1	Manufacturing includes this specific conversion step
trifluoroacetyl copolymer-1 + aqueous piperidine → copolymer-1	Manufacturing includes this second conversion step
Purifying copolymer-1	Manufacturing includes purification and results in the required MW band

Where are the strongest invalidity vectors typically found for this type of claim?

A process-tied product claim is commonly challenged by three prior-art categories.

1) Anticipation by same-process prior disclosures

If earlier patents or publications already disclose:

deprotection via hydrobromic acid producing a trifluoroacetyl copolymer intermediate, followed by
aqueous piperidine treatment,
yielding Copolymer-1 with ~5–9 kDa,

then claim 1 becomes vulnerable to novelty and anticipation attacks.

2) Obviousness from combination of known deprotection chemistry and known MW targets

Even if not all elements appear in one document, a challenger may combine:

known acid deprotection approaches to trifluoroacetyl intermediates,
known piperidine-based deprotection,
and known MW fractionation or processing steps.

The MW window makes the combination strategy matter, because the challenger must still show that the process results in the specified band.

3) “About” interpretation limits

Claim construction of “about” can shift validity and infringement outcomes:

A broad construction could enlarge coverage into adjacent MW bands.
A narrow construction could confine the claim tightly and reduce overlap with prior art.

The presence of a tight MW window suggests the patentee aimed for narrower protection, which often makes “about” critical.

How the claim impacts design-around strategies

For competitors, design-around is most feasible by breaking at least one of the claim’s defining features.

Design-around levers aligned to claim 1

Design element in claim	Design-around tactic
MW 5 to 9 kDa	Shift distribution outside the band, then qualify characterization
Hydrobromic acid step	Use an alternative acid or deprotection sequence
Trifluoroacetyl intermediate	Use a different intermediate pathway
Aqueous piperidine	Use different base chemistry or non-piperidine route
Purification step requirement	Adjust the process such that the final product does not match purification-defined characteristics (or where purification is inherently different)

The most “direct” design-around is avoiding either:

the hydrobromic acid + trifluoroacetyl intermediate path, or
aqueous piperidine treatment.

What to conclude about the claim’s enforceable scope?

Claim 1 is narrow and chemically specific:

It is not a generic Copolymer-1 claim.
It is a Copolymer-1 claim with a specific MW band and a specific conversion sequence that includes:
- HBr reaction of protected copolymer-1 to a trifluoroacetyl intermediate, then
- aqueous piperidine treatment to Copolymer-1.

That combination means enforceable coverage likely turns on:

manufacturing documentation,
product characterization tied to MW distribution,
and process replication evidence.

Key Takeaways

Claim 1 scope is product-by-process: Copolymer-1 with MW about 5–9 kDa plus a defined HBr → trifluoroacetyl intermediate → aqueous piperidine → purification sequence.
The MW band and the two conversion steps (including the specific intermediate and the aqueous piperidine treatment) are the primary narrowing features.
FTO risk concentrates on competitors manufacturing Copolymer-1 that both:
- target the ~5–9 kDa MW window, and
- use the same deprotection/recovery chemistry chain.
Design-around is most achievable by shifting MW out of range and/or using a different deprotection chemistry that breaks the HBr/trifluoroacetyl/piperidine sequence.

FAQs

1) Is claim 1 a pure product claim?

No. It is a product-by-process claim: it defines Copolymer-1 by both a MW specification and a defined manufacturing sequence.

2) What is the tightest claim limiter?

The tightest limit is the combination of:

MW about 5 to 9 kDa, and
the specific chemical steps that produce Copolymer-1 via a trifluoroacetyl intermediate using hydrobromic acid and then aqueous piperidine.

3) If a competitor makes Copolymer-1 in the same MW range but using different deprotection steps, does claim 1 necessarily read on it?

Not necessarily. The claim’s product is tied to the process-defined route, so a different deprotection sequence can avoid the claimed process limitations.

4) If a competitor uses the same chemistry but ends up outside 5–9 kDa, does it likely fall outside claim scope?

Yes. The claim requires Copolymer-1 having MW about 5–9 kDa, so producing outside that band typically avoids coverage.

5) What evidence is most relevant to proving infringement of a process-tied claim?

In practice, the highest-value evidence is:

process documentation or validated manufacturing records showing the HBr → trifluoroacetyl → aqueous piperidine steps, and
product characterization demonstrating MW distribution consistent with about 5–9 kDa.

References

[1] United States Patent No. 5,981,589 (claim 1 text as provided by user).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0762888	⤷ Start Trial	90987	Luxembourg	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300096	Netherlands	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300251	Netherlands	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,981,589

Summary for Patent: 5,981,589